Pliant Therapeutics Inc
F:9PT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pliant Therapeutics Inc
F:9PT
|
US |
|
T
|
Tegna Inc
SWB:GTT
|
US |
|
P
|
PPG Industries Inc
BMV:PPG
|
US |
|
Klepierre SA
OTC:KLPEF
|
FR |
|
U
|
UniCredit SpA
OTC:UNCRY
|
IT |
|
C
|
Comstock Resources Inc
SWB:CX91
|
US |
|
B
|
Bio-Techne Corp
XBER:TE1
|
US |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
US |
|
N
|
Note AB (publ)
LSE:0GSS
|
SE |
|
New Oriental Education & Technology Group Inc
OTC:NWOEF
|
CN |
|
P
|
Pierre et Vacances SA
SWB:PV6
|
FR |
Pliant Therapeutics Inc
Pliant Therapeutics is a biotechnology company that develops drug candidates for fibrotic diseases, where the body makes too much scar tissue in organs such as the lungs. Its main focus has been on medicines that block integrins, proteins that help drive the scarring process. The company is still in the drug-development stage, so it does not sell a commercial medicine yet. Pliant’s work is aimed at patients with serious diseases like pulmonary fibrosis, along with the doctors and hospitals that run clinical trials for these treatments. The company spends most of its time and capital on research, testing, and clinical studies rather than manufacturing or selling products. If a candidate medicine succeeds, it could be sold directly or through a partner to physicians treating these patients. The company makes money mainly through collaboration deals, licensing arrangements, and related research payments tied to its drug programs, with the longer-term goal of earning product sales or royalties if a medicine is approved. What makes its business different is that it is focused on a narrow but difficult class of diseases where the market depends on getting new drugs through years of testing and regulatory review before any commercial sales begin.
Pliant Therapeutics is a biotechnology company that develops drug candidates for fibrotic diseases, where the body makes too much scar tissue in organs such as the lungs. Its main focus has been on medicines that block integrins, proteins that help drive the scarring process. The company is still in the drug-development stage, so it does not sell a commercial medicine yet.
Pliant’s work is aimed at patients with serious diseases like pulmonary fibrosis, along with the doctors and hospitals that run clinical trials for these treatments. The company spends most of its time and capital on research, testing, and clinical studies rather than manufacturing or selling products. If a candidate medicine succeeds, it could be sold directly or through a partner to physicians treating these patients.
The company makes money mainly through collaboration deals, licensing arrangements, and related research payments tied to its drug programs, with the longer-term goal of earning product sales or royalties if a medicine is approved. What makes its business different is that it is focused on a narrow but difficult class of diseases where the market depends on getting new drugs through years of testing and regulatory review before any commercial sales begin.
